2023年6月26日

收到一封電子郵件在發布新文章時請提供您的電子郵件地址來接收電子郵件當張貼新文章。請稍後再試。如果你繼續這個問題請聯係customerservice@slackinc.com。回到Healio關鍵外賣:根據製造商,lyt - 300有潛力治療疾病包括焦慮和產後抑鬱症。在治療焦慮的一項研究結果預計將在2023年底。波士頓biotherapeutics公司宣布啟動第二階段的概念驗證臨床試驗在健康誌願者口服前藥的內源性allopregnanolone使用焦慮的臨床模型進行驗證。根據PureTech發布健康plc, lyt - 300有潛力治療一係列神經和神經精神障礙包括焦慮症和產後抑鬱症。lyt - 300是使用PureTech GlyphTM開發平台,利用人體的天然脂質吸收和運輸過程促進口腔攝入的藥物,否則不能直接口服,每釋放。PureTech健康宣布它已經開始第二階段試驗口服治療焦慮。圖片:Adobe股票“焦慮症是最常見的精神障礙,影響近30%的成年人在他們的生活。 Despite this, there has been very little clinical development in the last 20 years,” Eric Elenko, PhD, chief innovation officer at PureTech, said in the release. “We look forward to the results of this study as well as the initiation of a study with LYT-300 in postpartum depression later this year.” The FDA had previously approved a 60-hour IV formulation of allopregnanolone to treat PPD. PureTech expects results for the ongoing placebo-controlled trial by the end of 2023, while a separate open-label, phase 2a, proof-of-concept clinical trial in patients with PPD is expected to begin in the latter half of this year. Read more about